Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7321 to 7335 of 8236 results

  1. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

    Interventional procedures guidance
    Discontinued

  5. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

    Interventional procedures guidance
    Discontinued

  6. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

    Interventional procedures guidance
    In development

  7. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

    Interventional procedures guidance
    Discontinued

  8. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  9. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  10. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  11. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

    Technology appraisal guidance
    Discontinued

  12. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  13. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  14. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  15. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued